181 related articles for article (PubMed ID: 18086344)
21. Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas.
Kantarjian HM
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S1-2. PubMed ID: 18086341
[No Abstract] [Full Text] [Related]
22. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
23. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
24. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP.
Davenne T; Klintman J; Sharma S; Rigby RE; Blest HTW; Cursi C; Bridgeman A; Dadonaite B; De Keersmaecker K; Hillmen P; Chabes A; Schuh A; Rehwinkel J
Cell Rep; 2020 May; 31(6):107640. PubMed ID: 32402273
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for inhibition of human PNP by immucillin-H.
Filgueira de Azevedo W; Canduri F; Marangoni dos Santos D; Pereira JH; Dias MV; Silva RG; Mendes MA; Basso LA; Palma MS; Santos DS
Biochem Biophys Res Commun; 2003 Oct; 309(4):917-22. PubMed ID: 13679061
[TBL] [Abstract][Full Text] [Related]
26. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
Balakrishnan K; Burger JA; Quiroga MP; Henneberg M; Ayres ML; Wierda WG; Gandhi V
Blood; 2010 Aug; 116(7):1083-91. PubMed ID: 20442367
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
28. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
29. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
31. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
32. New catalytic mechanism for human purine nucleoside phosphorylase.
Canduri F; Fadel V; Basso LA; Palma MS; Santos DS; de Azevedo WF
Biochem Biophys Res Commun; 2005 Feb; 327(3):646-9. PubMed ID: 15649395
[TBL] [Abstract][Full Text] [Related]
33. [Some inhibitors of purine nucleoside phosphorylase].
Pogosian LG; Nersesova LS; Gazariants MG; Mkrtchian ZS; Akopian ZhI
Biomed Khim; 2011; 57(5):526-34. PubMed ID: 22629603
[TBL] [Abstract][Full Text] [Related]
34. Structure of human PNP complexed with ligands.
Canduri F; Silva RG; dos Santos DM; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2005 Jul; 61(Pt 7):856-62. PubMed ID: 15983407
[TBL] [Abstract][Full Text] [Related]
35. [Purine nucleoside phosphorylase inhibitors and their clinical significance].
Pogosian LG; Nersesova LS; Gazariants MG; Mkrtchian ZS; Meliksetian GO; Akopian ZhI
Ukr Biokhim Zh (1999); 2008; 80(5):95-104. PubMed ID: 19248622
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition of activity of purine nucleoside phosphorylase with N9- and N7-(beta-D-glucofuranuronosyl)purines and 8-substituted N9-(beta-D-ribofuranosyl)purines)].
Anan'ev AV; Maurin'sh IuA; Paégle RA; Lidak MIu; Akopian ZhI
Bioorg Khim; 1991 Jun; 17(6):855-6. PubMed ID: 1776970
[TBL] [Abstract][Full Text] [Related]
37. Mycoplasma hyorhinis-encoded purine nucleoside phosphorylase: kinetic properties and its effect on the cytostatic potential of purine-based anticancer drugs.
Vande Voorde J; Liekens S; Balzarini J
Mol Pharmacol; 2013 Dec; 84(6):865-75. PubMed ID: 24068428
[TBL] [Abstract][Full Text] [Related]
38. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.
Gilbertsen RB; Scott ME; Dong MK; Kossarek LM; Bennett MK; Schrier DJ; Sircar JC
Agents Actions; 1987 Aug; 21(3-4):272-4. PubMed ID: 3120507
[TBL] [Abstract][Full Text] [Related]
39. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency.
Cohen A; Gudas LJ; Ammann AJ; Staal GE; Martin DW
J Clin Invest; 1978 May; 61(5):1405-9. PubMed ID: 96138
[TBL] [Abstract][Full Text] [Related]
40. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
